Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Preventive Vaccines Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The preventive vaccines market size has experienced strong growth in recent years. It is projected to expand from $83 billion in 2025 to $90.33 billion in 2026, at a compound annual growth rate (CAGR) of 8.8%. The growth observed in the historic period can be attributed to the eradication and control of infectious diseases, government-led vaccination initiatives, rising public health awareness, the establishment of global immunization programs, and increased funding from international health organizations.
The preventive vaccines market is projected to experience robust expansion over the coming years, reaching a valuation of $131.27 billion in 2030, driven by a compound annual growth rate (CAGR) of 9.8%. This anticipated growth during the forecast period is fueled by several factors, including the advancement of next-generation vaccine technologies, the increasing global population and urbanization, enhanced outbreak readiness efforts, the broadening of adult immunization campaigns, and a rise in public–private collaborations for vaccine development. Key trends expected during this period involve the extension of national immunization programs, a heightened emphasis on preventive healthcare and disease management, growing demand for both pediatric and geriatric vaccinations, an increase in the development of combination and multivalent vaccines, and improvements in cold chain and vaccine storage facilities.
Get A Free Sample Report With In-Depth Market Insights:
Preventive Vaccines Market Industry Drivers: What’s Behind The Revenue Growth?
The rising occurrence of infectious diseases is anticipated to boost the expansion of the preventive vaccines market in the future. These diseases are conditions caused by harmful microorganisms like bacteria, viruses, fungi, or parasites, capable of spreading between individuals or via the environment. Their growing prevalence stems from factors such as increased urbanization, international travel, and antimicrobial resistance, which contribute to the quicker dissemination and greater difficulty in managing infections. Preventive vaccines play a crucial role in managing infectious diseases by priming the immune system to identify and combat pathogens prior to infection, consequently lowering disease rates and spread. As an example, the World Health Organization, an intergovernmental body based in Switzerland, reported in 2024 that global newly diagnosed TB (tuberculosis) cases hit 8.2 million in 2023, an increase from 7.5 million in 2022. Consequently, the expanding occurrence of infectious diseases is propelling the growth of the preventive vaccines market.
Preventive Vaccines Market Segments: Where Is Growth Concentrated?
The preventive vaccines market covered in this report is segmented –
1) By Type: Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines
2) By Disease Type: Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, Other Disease Types
3) By Age Group: Pediatric, Adult, Geriatric
4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Other Distribution Channels
Subsegments:
1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine, Varicella (Chickenpox) Vaccine, Oral Polio Vaccine (OPV), Yellow Fever Vaccine, Rotavirus Vaccine, Bacillus Calmette-Guérin (BCG) Vaccine
2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV), Hepatitis A Vaccine, Rabies Vaccine, Influenza (Inactivated) Vaccine, Japanese Encephalitis Vaccine
3) By Toxoid Vaccines: Tetanus Toxoid Vaccine, Diphtheria Toxoid Vaccine, Pertussis (whooping cough) Vaccine
4) By Subunit Vaccines: Hepatitis B Vaccine, Human Papillomavirus (HPV) Vaccine, Pertussis (acellular) Vaccine, Influenza (recombinant protein) Vaccine
5) By Conjugate Vaccines: Pneumococcal Conjugate Vaccine (PCV), Haemophilus influenzae type b (Hib) Vaccine, Meningococcal Conjugate Vaccine
6) By DNA Vaccines: Zika Virus DNA Vaccine, Cytomegalovirus (CMV) DNA Vaccine, Infectious Disease DNA Vaccines
7) By Recombinant Vector Vaccines: Ebola Vaccine (rVSV-ZEBOV), COVID-19 Recombinant Vector Vaccines, Dengue Recombinant Vector Vaccines
#Preventive Vaccines Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies within the preventive vaccines sector are prioritizing innovations in vaccine science, particularly advanced mRNA technology platforms. This focus aims to boost vaccine effectiveness, refine safety characteristics, accelerate development and production, and offer wider defense against new strains of infectious illnesses. These sophisticated mRNA technology platforms represent state-of-the-art techniques utilizing messenger RNA to direct cellular protein synthesis, thereby initiating a precise immunological reaction. As an illustration, in March 2025, Moderna Inc., a biotechnology firm located in the US, declared FDA clearance for mRNA-1283 (mNEXSPIKE), which is a novel COVID-19 vaccine. Its authorization covers adults 65 and older, alongside individuals aged 12–64 who possess at least one risk factor as specified by the CDC. The introduction of mNEXSPIKE signifies a major stride in the evolution of next-generation mRNA vaccine technology, providing enhanced stability and simpler storage requirements when contrasted with previous iterations. This progression is anticipated to improve the availability and distribution of vaccines, especially within marginalized and distant regions.
Preventive Vaccines Market Key Participants And Competitive Landscape
Major companies operating in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd.
View The Full Preventive Vaccines Market Report:
Preventive Vaccines Market Regional Outlook: Where Is Opportunity Concentrated?
North America was the largest region in the preventive vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preventive vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Leave a Reply